Literature DB >> 7796954

Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.

G Sutter1, B Moss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7796954

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN： 0301-5149


× No keyword cloud information.
  14 in total

Review 1.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

Review 3.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

4.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

6.  Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Authors:  James T Snyder; Igor M Belyakov; Amiran Dzutsev; François Lemonnier; Jay A Berzofsky
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

9.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.

Authors:  G S Taylor; T A Haigh; N H Gudgeon; R J Phelps; S P Lee; N M Steven; A B Rickinson
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.